Current Report Filing (8-k)
June 12 2020 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 9, 2020
IGM
Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39045
|
|
77-0349194
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
325 E. Middlefield Road
Mountain View, CA 94043
(Address of principal executive offices, including zip code)
(650) 965-7873
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value
$0.01 per share
|
|
IGMS
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On June 9, 2020, the Board of Directors of IGM Biosciences, Inc. (the Company) approved the Companys amended and restated bylaws (the
Amended and Restated Bylaws) to amend Article XI - Exclusive Forum to provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the
exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.
The Amended
and Restated Bylaws are attached hereto as Exhibit 3.1 and are hereby incorporated by reference into this Item 5.03. The foregoing summary description does not purport to be complete and is qualified in its entirety by reference to the full
text of the Amended and Restated Bylaws.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 9, 2020, the Company held its 2020 Annual Meeting of Stockholders (the Annual Meeting). Of the 24,128,065 shares of common stock of
the Company outstanding as of April 16, 2020, the record date for the meeting, 22,661,578 shares of common stock were present in person (including virtually) or represented by proxy at the Annual Meeting, constituting a quorum for the
transaction of business. The proposals voted upon at the meeting and the final voting results with respect to each proposal are as set forth below.
Proposal 1: Election of Directors
Each of the following
nominees was elected to serve as a Class I director to serve until the Companys 2023 annual meeting of stockholders or until his or her respective successor is duly elected and qualified.
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
Julie Hambleton, M.D.
|
|
|
18,546,218
|
|
|
|
2,389,471
|
|
|
|
1,725,889
|
|
William Strohl, Ph.D.
|
|
|
18,545,218
|
|
|
|
2,390,471
|
|
|
|
1,725,889
|
|
Jakob Haldor Topsøe
|
|
|
18,545,218
|
|
|
|
2,390,471
|
|
|
|
1,725,889
|
|
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm
The appointment of Deloitte & Touche LLP as the Companys independent registered public accounting firm for the Companys fiscal year ending
December 31, 2020 was ratified.
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
|
Against
|
|
|
Abstain
|
|
|
Broker
Non-Votes
|
|
22,656,497
|
|
|
|
2,190
|
|
|
|
2,891
|
|
|
N/A
|
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
IGM BIOSCIENCES, INC.
|
|
|
By:
|
|
/s/ Misbah Tahir
|
|
|
Misbah Tahir
|
|
|
Chief Financial Officer
|
Date: June 12, 2020
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jul 2024 to Aug 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Aug 2023 to Aug 2024